1. Home
  2. GRND vs DFTX Comparison

GRND vs DFTX Comparison

Compare GRND & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grindr Inc.

GRND

Grindr Inc.

HOLD

Current Price

$12.27

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.55

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GRND
DFTX
Founded
2009
N/A
Country
United States
United States
Employees
148
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRND
DFTX
Price
$12.27
$20.55
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$19.67
$40.25
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$17.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.79
$14.62
52 Week High
$25.13
$21.10

Technical Indicators

Market Signals
Indicator
GRND
DFTX
Relative Strength Index (RSI) 53.22 63.40
Support Level $11.83 $16.41
Resistance Level $12.90 N/A
Average True Range (ATR) 0.46 1.09
MACD -0.07 0.23
Stochastic Oscillator 39.19 82.97

Price Performance

Historical Comparison
GRND
DFTX

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: